{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:29:57Z","timestamp":1753273797896},"reference-count":38,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.3892\/ol.2017.6331","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T05:29:19Z","timestamp":1496813359000},"page":"1373-1378","source":"Crossref","is-referenced-by-count":15,"title":["PI3K\/AKT\/mTOR pathway in pulmonary carcinoid tumours"],"prefix":"10.3892","volume":"14","author":[{"given":"Zixuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"key20180108115039_b1-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"key20180108115039_b2-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0169-5002(02)00080-6","article-title":"Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark","volume":"37","author":"Skuladottir","year":"2002","journal-title":"Lung Cancer"},{"key":"key20180108115039_b3-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.119.1.14","article-title":"The surgical spectrum of pulmonary neuroendocrine neoplasms","volume":"119","author":"Cooper","year":"2001","journal-title":"Chest"},{"key":"key20180108115039_b4-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e31825493eb","article-title":"Development of PI3K\/AKT\/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer","volume":"7","author":"Papadimitrakopoulou","year":"2012","journal-title":"J Thorac Oncol"},{"key":"key20180108115039_b5-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"key20180108115039_b6-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10555-011-9290-3","article-title":"Innovations therapy: Mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors","volume":"30","author":"Capdevila","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"key20180108115039_b7-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","article-title":"The Akt-mTOR tango and its relevance to cancer","volume":"8","author":"Hay","year":"2005","journal-title":"Cancer Cell"},{"key":"key20180108115039_b8-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.mrrev.2008.06.001","article-title":"The mTOR pathway and its role in human genetic diseases","volume":"659","author":"Rosner","year":"2008","journal-title":"Mutat Res"},{"key":"key20180108115039_b9-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(07)38021-X","article-title":"Characterization of the Rheb-mTOR signaling pathway in mammalian cells: Constitutive active mutants of Rheb and mTOR","volume":"438","author":"Sato","year":"2008","journal-title":"Methods Enzymol"},{"key":"key20180108115039_b10-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol Med"},{"key":"key20180108115039_b11-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108115039_b12-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"key20180108115039_b13-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"key20180108115039_b14-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/1078-0432.CCR-07-1041","article-title":"Dissecting the Akt\/mammalian target of rapamycin signaling network: Emerging results from the head and neck cancer tissue array initiative","volume":"13","author":"Molinolo","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"R1","key":"key20180108115039_b15-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1093\/hmg\/ddp032","article-title":"Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment","volume":"18","author":"Inoki","year":"2009","journal-title":"Hum Mol Genet"},{"key":"key20180108115039_b16-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"31616","DOI":"10.1074\/jbc.M603107200","article-title":"Caffeine targets TOR complex I and provides evidence for a regulatory link between the FRB and kinase domains of Tor1p","volume":"281","author":"Reinke","year":"2006","journal-title":"J Biol Chem"},{"key":"key20180108115039_b17-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet"},{"key":"key20180108115039_b18-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1357-4310(98)01245-3","article-title":"The genetic basis of tuberous sclerosis","volume":"4","author":"Young","year":"1998","journal-title":"Mol Med Today"},{"key":"key20180108115039_b19-ol-0-0-6331","doi-asserted-by":"crossref","unstructured":"CarsilloTAstrinidisAHenskeEPMutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosisProc Natl Acad Sci USA9760856090200010.1073\/pnas.97.11.608510823953","DOI":"10.1073\/pnas.97.11.6085"},{"key":"key20180108115039_b20-ol-0-0-6331","unstructured":"VoortmanJLeeJHKillianJKSuuriniemiMWangYLucchiMSmithWJMeltzerPWangYGiacconeGArray comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumorsProc Natl Acad Sci USA1071304013045201010.1073\/pnas.100813210720615970"},{"key":"key20180108115039_b21-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"C15","DOI":"10.1530\/ERC-10-0290","article-title":"mTOR inhibition, a potential novel approach for bronchial carcinoids","volume":"18","author":"Dong","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"key20180108115039_b22-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/ERC-13-0042","article-title":"mTOR, p70S6K, AKT, and ERK1\/2 levels predict sensitivity to mTOR and PI3K\/mTOR inhibitors in human bronchial carcinoids","volume":"20","author":"Gagliano","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"key20180108115039_b23-ol-0-0-6331","volume-title":"Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2004"},{"key":"key20180108115039_b24-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"key":"key20180108115039_b25-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1158\/1078-0432.CCR-09-0099","article-title":"High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma","volume":"15","author":"Anagnostou","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180108115039_b26-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00428-012-1239-6","article-title":"Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer","volume":"460","author":"Oh","year":"2012","journal-title":"Virchows Arch"},{"key":"key20180108115039_b27-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1677\/ERC-10-0157","article-title":"Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung","volume":"17","author":"Righi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"key20180108115039_b28-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)65653-2","article-title":"Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization","volume":"153","author":"Walch","year":"1998","journal-title":"Am J Pathol"},{"key":"key20180108115039_b29-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0046-8177(98)90428-2","article-title":"Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization","volume":"29","author":"Ullmann","year":"1998","journal-title":"Hum Pathol"},{"key":"key20180108115039_b30-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0002-9440(10)64780-3","article-title":"Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): Marked differences indicating diversity in molecular pathogenesis","volume":"157","author":"Zhao","year":"2000","journal-title":"Am J Pathol"},{"key":"key20180108115039_b31-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.10049","article-title":"The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissues","volume":"34","author":"Ullmann","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180108115039_b32-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3858\/emm.2009.41.5.039","article-title":"Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential","volume":"41","author":"Warth","year":"2009","journal-title":"Exp Mol Med"},{"key":"key20180108115039_b33-ol-0-0-6331","first-page":"1145","article-title":"Comparative integromics on Angiopoietin family members","volume":"17","author":"Katoh","year":"2006","journal-title":"Int J Mol Med"},{"key":"key20180108115039_b34-ol-0-0-6331","first-page":"1411","article-title":"The tuberous sclerosis genes, TSC1 and TSC2, trigger different gene expression responses","volume":"27","author":"Rosner","year":"2005","journal-title":"Int J Oncol"},{"key":"key20180108115039_b35-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"key20180108115039_b36-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: Analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"key":"key20180108115039_b37-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1677\/ERC-10-0097","article-title":"Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids","volume":"17","author":"Zatelli","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"key20180108115039_b38-ol-0-0-6331","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T14:03:30Z","timestamp":1569420210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.6331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,7]]},"published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3892\/ol.2017.6331"],"URL":"https:\/\/doi.org\/10.3892\/ol.2017.6331","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}